Cleveland Clinic, a nonprofit American academic medical center, led an $33m Series B funding round in Centerline Biomedical, a biotechnology company, with participation from GE Healthcare, RIK Enterprises, JobsOhio, Jumpstart Ventures and G2 Group Ventures. "Our technology is already yielding excellent clinical benefits and this funding will help realize our mission of improving the outcomes, radiation safety and accuracy in endovascular surgery. Successfully raising this capital given the challenging global environment is a resounding testament to this technology and incredible team at Centerline," Philip D. Rackliffe, Centerline Biomedical CEO.